Quarterly revenue growth rates and guidance revisions - market expects sustained 25-30% growth trajectory
Gross margin expansion trends indicating manufacturing scale efficiencies and yield improvements
Large pharma partnership announcements for antibody discovery or therapeutic development programs
Progress on DNA data storage commercialization with tech companies (Microsoft, Illumina partnerships)
moderate - Research and development spending by pharma/biotech customers shows resilience through cycles as drug pipelines require continuous investment, but academic/government research funding can contract during recessions. Approximately 70% of revenue from commercial customers provides buffer versus purely grant-funded businesses. Biotech funding environment (venture capital, IPO markets) significantly impacts customer spending capacity, particularly for smaller emerging biotech clients. Industrial production weakness would not directly impact but correlates with broader risk appetite affecting biotech sector.
Rising rates create headwinds through multiple channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies like Twist, (2) Tighter financial conditions reduce biotech customer access to capital, constraining R&D budgets, (3) Increased cost of capital for Twist's own expansion investments and potential future debt financing. However, large pharma customers (less rate-sensitive) represent significant revenue base. Company's strong balance sheet (3.78x current ratio, minimal debt) provides insulation from direct financing pressure.
Technological obsolescence if competitors develop superior synthesis methods or if CRISPR/gene editing reduces need for synthetic DNA in certain applications
Pricing pressure as synthetic biology becomes commoditized - incumbent suppliers (IDT/Agilent) have larger scale and could engage in price competition
Regulatory changes affecting gene synthesis oversight, particularly for dual-use sequences or biosecurity concerns requiring screening protocols
growth - Investors focused on disruptive life sciences technology with long-term market expansion potential. Stock appeals to thematic investors in synthetic biology, genomics, and biotech innovation. High revenue growth (20%+) but sustained losses attract growth-at-reasonable-price investors willing to accept 3-5 year profitability timeline. Recent 95% three-month return indicates momentum investor participation. Not suitable for value or income investors given negative earnings, no dividend, and premium valuation (8.1x P/S).
Trend
-5.7% vs SMA 50 · +28.3% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $374.8M $374.0M–$375.3M | — | -$1.31 | — | ±6% | High5 |
FY2026(current) | $446.6M $440.6M–$449.8M | ▲ +19.2% | -$2.05 | — | ±7% | High6 |
FY2027 | $518.7M $498.6M–$537.4M | ▲ +16.1% | -$1.37 | — | ±2% | High7 |
INSTITUTIONAL OWNERSHIP
TWST News
About
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
TWST◀ | $49.17 | -7.14% | $3.1B | — | +2032.1% | -2062.6% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.56% | — | 50.3 | +342140.1% | -3796.6% | 1500 |